TORL BioTherapeutics

United States
Los Angeles, California, United States

Company profile

TORL BioTherapeutics company profile

TORL BioTherapeutics is a clinical-stage biopharmaceutical business focused on creating innovative, antibody-based medicines to improve the lives of cancer patients. They are developing a comprehensive pipeline of innovative preclinical ADCs and mAb in oncologic diseases with high unmet medical needs.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Founded
2018-01-01, Year

Headquarters

Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Late Stage Venture
Funding rounds
3
Total equity funding
$412M
Last funding
Series C / $96M / 2025-10-07
Last equity funding
Series C / $96M
Investors
18
Lead investors
2
Articles
49

Founders and investors

Lead investors

Deep Track CapitalGoldman Sachs Asset Management

Investors

Blue OwlBristol-Myers SquibbGoldman SachsPerceptive AdvisorsRA Capital Management